Abstract:Background. Elevated uric acid (UA) has been found to damage pancreatic β-cell, promote oxidative stress, and cause insulin resistance in type 2 diabetes (T2D). Astragaloside IV (AS-IV), a major active monomer extracted from Astragalus membranaceus (Fisch.) Bunge. which belongs to TRIB. Galegeae (Br.) Torrey et Gray, Papilionaceae, exhibits various activities in a pathophysiological environment and has been widely employed to treat diseases. However, the effects of AS-IV on UA-induced pancreatic β-cell damage need to be investigated and the associating mechanism needs to be elucidated. This study was designed to determine the protective effects and underlying mechanism of AS-IV on UA-induced pancreatic β-cell dysfunction in T2D. Methods. UA-treated Min6 cells were exposed to AS-IV or wortmannin. Thereafter, the 3-(45)-dimethylthiahiazo(-z-y1)-35-di-phenytetrazoliumromide (MTT) assay and flow cytometry were employed to determine the effect of AS-IV on cell proliferation and apoptosis, respectively. Insulin secretion was evaluated using the glucose-stimulated insulin secretion (GSIS) assay. Finally, western blot and quantitative real-time polymerase chain reaction (qRT-PCR) were performed to determine the effect of AS-IV on the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) pathway in UA-treated cells. Results. AS-IV had no cytotoxic effects on Min6 cells. UA significantly suppressed Min6 cell growth, promoted cell apoptosis, and enhanced caspase-3 activity; however, AS-IV abolished these effects in a dose-dependent manner. Further, decreased insulin secretion was found in UA-treated Min6 cells compared to control cells, and the production of insulin was enhanced by AS-IV in a dose-dependent manner. AS-IV significantly increased phosphorylated (p)-AKT expression and the ratio of p-AKT/AKT in Min6 cells exposed to UA. No evident change in AKT mRNA level was found in the different groups. However, the effects of AS-IV on UA-stimulated Min6 cells were reversed by 100 nM wortmannin. Conclusion. Collectively, our data suggest that AS-IV protected pancreatic β-cells from UA-treated dysfunction by activating the PI3K/AKT pathway. Such findings suggest that AS-IV may be an efficient natural agent against T2D.

Astragaloside IV improved barrier dysfunction induced by acute high glucose in human umbilical vein endothelial cells.

Effects of High Glucose on the Activity of GSH-PX,the Expressions of NOS and ICAM-1 in Human Umbilical Vein Endothelial Cells

Astragaloside IV inhibits proliferation and promotes apoptosis in rat vascular smooth muscle cells under high glucose concentration in vitro.

Effect of Astragaloside IV on Hepatic Glucose‐regulating Enzymes in Diabetic Mice Induced by a High‐fat Diet and Streptozotocin

Astragaloside Iv Stimulates Angiogenesis And Increases Hypoxia-Inducible Factor-1 Alpha Accumulation Via Phosphatidylinositol 3-Kinase/Akt Pathway

Astragaloside IV Improves High Glucose-Induced Podocyte Adhesion Dysfunction Via Alpha3beta1 Integrin Upregulation and Integrin-Linked Kinase Inhibition.

Effects of Astragaloside IV Protect Against Podocyte Lesion Exposed to High Glucose

Effects of Astragaloside IV on Pathogenesis of Metabolic Syndrome in Vitro

Astragaloside IV improves vascular endothelial dysfunction by inhibiting the TLR4/NF-κB signaling pathway

Astragalosides IV Inhibits High Glucose-Induced Cell Apoptosis Through HGF Activation in Cultured Human Tubular Epithelial Cells.

Astragaloside IV Prevents High Glucose-Induced Podocyte Apoptosis Via Downregulation of TRPC6.

Astragaloside Iv, A Novel Antioxidant, Prevents Glucose-Induced Podocyte Apoptosis in Vitro and in Vivo

Astragaloside IV attenuates high glucose‐induced NF‐κB‐mediated inflammation through activation of PI3K/AKT‐ERK‐dependent Nrf2/ARE signaling pathway in glomerular mesangial cells

Astragaloside-IV Protects H9C2(2-1) Cardiomyocytes from High Glucose-Induced Injury Via Mir-34A-mediated Autophagy Pathway.

Effects of high glucose and Astragalus Membranaceus on the number, proliferation, and differentiation of endothelial progenitor cells from human peripheral blood in vitro

Protective Effects of Astragalosides Ⅳ on the Renal Tubular Epithelial Cell Injury Induced by High Glucose

Effects of Astragalus on Expression of Apelin/APJ in Human Umbilical Vein Endothelial Cells Exposed to High Glucose

Astragaloside IV attenuates glycated albumin-induced epithelial-to-mesenchymal transition by inhibiting oxidative stress in renal proximal tubular cells

Protective Effects of Astragaloside IV on High Glucose Induced Cardiac Myocytes Hypertrophy in Neonatal Rats

Rapid Analysis and Guided Isolation of Astragalus Isoflavonoids by UHPLC-DAD-MSn and Their Cellular Antioxidant Defense on High-Glucose-Induced Mesangial Cell Dysfunction

Protective Effects of Astragaloside IV on Uric Acid-Induced Pancreatic β-Cell Injury through PI3K/AKT Pathway Activation